Investigation announced for Long-Term Investors in shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) over potential Wrongdoing

An investigation was announced for current long-term investors in shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) concerning potential breaches of fiduciary duties by certain directors of DENTSPLY SIRONA Inc.

Investors who are current long term investors in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: XRAY stocks follows a lawsuit filed against DENTSPLY SIRONA Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: XRAY stocks, concerns whether certain DENTSPLY SIRONA Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants made materially false and misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects, including that Dentsply targeted low-income people who did not have access to good oral hygiene education, a dentist, or dental insurance, which often meant patients signing up for Byte had underlying dental issues that would have made them ineligible for treatment, that the push for Byte growth and sales commissions caused sales employees to sell to contraindicated patients, that as a result of the above, the Byte patient onboarding workflow did not provide adequate assurance that contraindicated patients did not enter treatment, that before and during the Class Period, reports of Byte patient injuries were pouring in, that Dentsply knew that its Byte aligners were causing severe patient injuries for years but did little to investigate those injuries or notify the FDA, that Dentsply had no systems in place to notify the FDA of these injuries, which the Company is required to do within 30 days of learning of a problem, that the FDA had received a sharp uptick in reports of serious injuries from Byte patients, that as a result of the above, Dentsply materially overstated the goodwill value of Byte, and that as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.